Breast Cancer

Fulvestrant Targets And Degrades Estrogen Receptor

Published in Women's Health Weekly, April 19th, 2001

AstraZeneca announced on March 29, 2001, that it submitted a new drug application (NDA) requesting Priority Review with the U.S. Food and Drug Administration (FDA) for Faslodex^TM (fulvestrant) for treatment of locally advanced or metastatic breast cancer in postmenopausal women who have previously progressed following hormonal therapy.

Faslodex is characterized as an estrogen receptor downregulator and works differently than other hormonal breast cancer drugs in that it targets and degrades the estrogen receptor. Currently, advanced breast cancer patients whose tumors have been shown to use hormones to grow, are given drugs like tamoxifen that act by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry